Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Amphastar Pharmaceuticals (AMPH) EBT Margin (2016 - 2026)

Amphastar Pharmaceuticals has reported EBT Margin over the past 13 years, most recently at 20.34% for Q4 2025.

  • For Q4 2025, EBT Margin fell 613.0% year-over-year to 20.34%; the TTM value through Dec 2025 reached 17.91%, down 875.0%, while the annual FY2025 figure was 17.91%, 875.0% down from the prior year.
  • EBT Margin for Q4 2025 was 20.34% at Amphastar Pharmaceuticals, up from 11.21% in the prior quarter.
  • Over five years, EBT Margin peaked at 35.25% in Q3 2023 and troughed at 78.93% in Q4 2023.
  • A 5-year average of 12.74% and a median of 22.49% in 2021 define the central range for EBT Margin.
  • Biggest five-year swings in EBT Margin: plummeted -8612bps in 2022 and later skyrocketed 10540bps in 2024.
  • Year by year, EBT Margin stood at 22.47% in 2021, then tumbled by -383bps to 63.65% in 2022, then decreased by -24bps to 78.93% in 2023, then surged by 134bps to 26.47% in 2024, then decreased by -23bps to 20.34% in 2025.
  • Business Quant data shows EBT Margin for AMPH at 20.34% in Q4 2025, 11.21% in Q3 2025, and 22.55% in Q2 2025.